Asset Management One’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$342M Buy
372,209
+3,661
+1% +$3.71M 1.01% 14
2025
Q4
$398M Buy
368,548
+5,969
+2% +$5.71M 1.11% 14
2025
Q3
$277M Sell
362,579
-3,654
-1% -$2.72M 0.8% 16
2025
Q2
$285M Buy
366,233
+2,082
+0.6% +$1.62M 0.9% 16
2025
Q1
$301M Buy
364,151
+23,879
+7% +$19.9M 1.04% 16
2024
Q4
$266M Sell
340,272
-20,010
-6% -$16.6M 0.92% 14
2024
Q3
$319M Buy
360,282
+1,412
+0.4% +$1.27M 1.14% 12
2024
Q2
$325M Sell
358,870
-16,018
-4% -$12.8M 1.24% 11
2024
Q1
$292M Sell
374,888
-21,035
-5% -$15M 1.12% 11
2023
Q4
$230M Buy
395,923
+4,708
+1% +$2.75M 0.93% 16
2023
Q3
$210M Sell
391,215
-4,389
-1% -$2.26M 0.94% 14
2023
Q2
$186M Buy
395,604
+4,328
+1% +$1.82M 0.79% 18
2023
Q1
$134M Buy
391,276
+9,730
+3% +$3.28M 0.61% 25
2022
Q4
$140M Sell
381,546
-15,404
-4% -$5.46M 0.68% 22
2022
Q3
$128M Sell
396,950
-2,792
-0.7% -$885K 0.65% 23
2022
Q2
$130M Sell
399,742
-10,263
-3% -$3.08M 0.61% 26
2022
Q1
$117M Sell
410,005
-39,413
-9% -$10.1M 0.46% 35
2021
Q4
$125M Sell
449,418
-13,703
-3% -$3.47M 0.44% 40
2021
Q3
$107M Sell
463,121
-16,089
-3% -$3.97M 0.41% 43
2021
Q2
$110M Sell
479,210
-38,550
-7% -$7.74M 0.41% 42
2021
Q1
$96.7M Sell
517,760
-14,356
-3% -$2.81M 0.38% 48
2020
Q4
$88.7M Buy
532,116
+19,649
+4% +$2.93M 0.37% 53
2020
Q3
$75.9M Sell
512,467
-4,854
-0.9% -$751K 0.35% 52
2020
Q2
$84.9M Sell
517,321
-23,998
-4% -$3.68M 0.42% 46
2020
Q1
$75.1M Sell
541,319
-17,615
-3% -$2.42M 0.44% 45
2019
Q4
$73.5M Sell
558,934
-6,606
-1% -$766K 0.33% 62
2019
Q3
$63.2M Buy
565,540
+16,273
+3% +$1.81M 0.3% 70
2019
Q2
$60.9M Buy
549,267
+13,389
+2% +$1.58M 0.3% 67
2019
Q1
$69.5M Sell
535,878
-1,134,089
-68% -$138M 0.38% 51
2018
Q4
$193M Sell
1,669,967
-908
-0.1% -$101K 0.46% 43
2018
Q3
$179M Sell
1,670,875
-7,009
-0.4% -$701K 0.37% 54
2018
Q2
$143M Buy
1,677,884
+13,482
+0.8% +$1.11M 0.31% 67
2018
Q1
$129M Sell
1,664,402
-42,200
-2% -$3.4M 0.29% 77
2017
Q4
$144M Buy
1,706,602
+7,173
+0.4% +$610K 0.32% 64
2017
Q3
$145M Buy
1,699,429
+64,146
+4% +$5.26M 0.34% 61
2017
Q2
$135M Buy
1,635,283
+32,405
+2% +$2.64M 0.34% 58
2017
Q1
$135M Sell
1,602,878
-125,280
-7% -$10M 0.35% 58
2016
Q4
$127M Buy
1,728,158
+1,294,900
+299% +$96.4M 0.32% 65
2016
Q3
$34.6M Buy
433,258
+1,297
+0.3% +$104K 0.51% 33
2016
Q2
$33.8M Buy
431,961
+119,584
+38% +$9M 0.51% 32
2016
Q1
$22.4M Sell
312,377
-94,428
-23% -$7.15M 0.33% 63
2015
Q4
$35M Buy
406,805
+8,472
+2% +$703K 0.52% 33
2015
Q3
$32M Sell
398,333
-46,018
-10% -$3.88M 0.49% 30
2015
Q2
$37.2M Sell
444,351
-28,122
-6% -$2.14M 0.52% 29
2015
Q1
$34.9M Buy
472,473
+159,001
+51% +$11.3M 0.43% 33
2014
Q4
$22M Buy
313,472
+14,610
+5% +$986K 0.28% 68
2014
Q3
$19.5M Buy
298,862
+138,376
+86% +$8.76M 0.27% 79
2014
Q2
$10.1M Sell
160,486
-9,061
-5% -$541K 0.15% 159
2014
Q1
$9.79M Sell
169,547
-12,465
-7% -$696K 0.15% 159
2013
Q4
$9.32M Sell
182,012
-59,339
-25% -$2.97M 0.14% 166
2013
Q3
$12.2M Sell
241,351
-171,817
-42% -$9M 0.18% 123
2013
Q2
$20.4M Buy
+413,168
New +$22.5M 0.33% 72

Other funds holding LLY

Asset Management One's LLY Position: Q1 2026 in Review

Asset Management One increased its Eli Lilly (LLY) stake by 0.99% in Q1 2026, buying an estimated $3.71M and bringing the position to 372,209 shares worth $342M. The position accounts for 1.01% of the portfolio, ranked #14.

Asset Management One first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $398M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Asset Management One held 372,209 shares of Eli Lilly worth $342M as of Q1 2026.
  • Asset Management One bought 3,661 Eli Lilly shares in Q1 2026, an estimated $3.71M.
  • Eli Lilly made up 1.01% of Asset Management One's portfolio in Q1 2026, its #14 holding.
  • Asset Management One first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Asset Management One's Eli Lilly position peaked at $398M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Asset Management One's 13F filing for Q1 2026, filed 8 May 2026.